Inflammatory bowel diseases (IBDs) treatments have shifted from small-molecular
therapeutics to the oncoming biologics. The first-line biologics against the moderate-to …

Inflammatory bowel disease (IBD) is a GI tract disorder that manifests as either Ulcerative
colitis (UC) or Crohn's disease (CD). The precise etiology of IBD is still not completely …

Abstract Treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with
the development of biologics and small molecule drugs (SMDs). However, these drugs are …

Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by
gastrointestinal tract inflammation. It is caused by the interplay of the host's genetic …

Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the
intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease …

Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and
whose incidence is increasing over the world. There is currently no cure for IBD, and the …

The emergence of biologic therapies is arguably the greatest therapeutic advance in the
care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at …

Inflammatory bowel diseases (IBDs) are a group of debilitating inflammatory complications
specially inflicting colonic tissue in which full long term remission with current standardized …

Crohn's disease (CD) and ulcerative colitis (UC) are intestinal disorders that comprise the
inflammatory bowel diseases (IBD). These disorders have a significant effect on the quality …

New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom
control towards treat-to-target algorithms in order to optimize treatment results. The treatment …